Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 10.62B 9.48B 8.81B 8.02B 15.08B 1,006B 15.35B 106B 41.42B 525B 39.87B 39.02B 1,680B P/E 2026 *
-73.5x
P/E 2027 * 87.7x
Enterprise Value 10.1B 9.01B 8.38B 7.62B 14.33B 956B 14.59B 101B 39.37B 499B 37.89B 37.09B 1,597B EV / Sales 2026 *
6.6x
EV / Sales 2027 * 4.57x
Free-Float
94.17%
Yield 2026 *
-
Yield 2027 * -
1 day-0.04%
1 week-3.59%
Current month-8.76%
1 month-12.13%
3 months-16.44%
6 months-11.33%
Current year-21.04%
1 week 448.77
Extreme 448.769
478.84
1 month 448.77
Extreme 448.769
539.29
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 13.09
Extreme 13.0886
615
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Director/Board Member 74 2016-06-30
Director/Board Member 68 2016-08-10
Director/Board Member 64 2019-06-26
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Sell

Chief Executive Officer

-5,221 0.0226%
8/17/26 Sell

General Counsel

-664 0.0029%
8/15/26 Free

Director

1,725 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-3.59%+6.08%+227.57% 10.63B
+0.21%-4.63%+55.34%+71.32% 68.92B
+1.66%+7.51%+8.12%+60.04% 51.9B
+3.14%+7.17%+12.48%+44.42% 48.73B
+3.45%+4.70%+33.44%+35.96% 43.13B
-2.20%+0.61%+281.88%+532.76% 41.48B
+6.43%+6.84%+18.32%+109.23% 39.96B
+1.28%+1.39%+11.69%+45.10% 30.6B
+2.67%-7.30%+36.17%+1.88% 26.01B
+1.74%-2.02%-13.55%-12.92% 22.27B
Average +1.83%-1.21%+45.00%+111.54% 38.36B
Weighted average by Cap. +1.86%-0.34%+51.54%+108.88%

Financials

2026 *2027 *
Net sales 1.53B 1.37B 1.27B 1.15B 2.17B 145B 2.21B 15.24B 5.96B 75.58B 5.74B 5.62B 242B 2.12B 1.9B 1.76B 1.6B 3.01B 201B 3.07B 21.16B 8.28B 105B 7.97B 7.8B 336B
Net income -182M -162M -151M -137M -258M -17.23B -263M -1.81B -709M -8.99B -683M -668M -28.76B 173M 154M 143M 130M 245M 16.35B 250M 1.72B 673M 8.53B 648M 634M 27.3B
Net Debt -527M -470M -437M -398M -748M -49.91B -762M -5.25B -2.05B -26.04B -1.98B -1.94B -83.32B -924M -825M -767M -697M -1.31B -87.52B -1.34B -9.21B -3.6B -45.66B -3.47B -3.39B -146B
Projected Income Statement - Annual - Madrigal Pharmaceuticals, Inc.
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
26-10-15 US$459.81 -0.04% 266,163
26-10-14 US$460.01 +1.75% 326,944
26-10-13 US$452.12 -3.22% 315,930
26-10-12 US$467.16 -0.97% 469,270
26-10-09 US$471.75 -1.08% 312,998
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Madrigal Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
459.81USD
Average target price
685.78USD
Spread / Average Target
+49.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Madrigal Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. MDGL Stock